drugset / Trial / NCT00535197

Autologous Bone Marrow Stem Cells in Ischemic Stroke.

NCT00535197 ↗

Phase 1/2 Completed 5 enrolled Imperial College London
NaSingle-groupOpen-labelBasic science

Summary

The aim of the study is to determine the safety and tolerability of an autologous CD34+ subset bone marrow stem cell infusion into the middle cerebral artery in patients who have suffered acute total or partial anterior circulation syndrome (TACS/PACS).

Timeline

Start
2007-09
Primary completion
2012-07
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CD34+ stem cells Cell therapy — Other